Journal of Emerging Trends and Novel Research
JETNR.ORG | ISSN : 2984-9276
An International Open Access, Peer-reviewed, Refereed Journal

3D Micro Physiological Disease Modelling and Tissue Engineering

Susanta Bera*[1], Kushal Roy *[2]
Mrs. Mahalakshmi S*[3], Dr. Kavitha P N*[4]
*[12] Students, *[3] Asso professor, *[4] Principle
*[1] Pharmacy
*[1]K.R. College of Pharmacy, Bengaluru, Karnataka, India
beras4645@gmail.com, roykushal2589@gmail.com, mahalakshmisampagavi@yahoo.com

Abstract

One of the biggest obstacles to drug discovery and therapeutic development is the creation of trustworthy and predictive preclinical models. Drug attrition rates during clinical trials are significant because traditional two-dimensional cell cultures and animal models frequently fall short of correctly simulating human physiology. In this context, three-dimensional (3D) micro physiological disease modelling combined with tissue engineering has emerged as a transformative technique to bridge the gap between in vitro investigations and human clinical outcomes. Important features of natural human tissues, such as three-dimensional design, extracellular matrix connections, mechanical pressures, and dynamic biochemical signalling, are replicated by 3D micro physiological systems. These systems offer physiologically relevant disease modelling across several organ systems by combining human-derived cells, microfluidics, and sophisticated biomaterials. Their implementation in drug screening allows more precise assessment of medication efficacy, toxicity, and pharmacokinetic behaviour compared to previous models.

Additionally, the use of induced pluripotent stem cells and patient-derived cells has increased the function of micro physiological systems in customized treatment. These patient-specific models allow precision medicine by predicting unique medication reactions and optimizing therapy tactics. Artificial intelligence and omics technologies work together to improve translational relevance, model validation, and data interpretation.

All things considered, tissue engineering and 3D micro physiological disease modelling are effective methods for increasing the effectiveness of medication discovery, lowering the need for animal testing, and developing individualized healthcare. Their implementation in pharmaceutical research and clinical applications is anticipated to accelerate with further technological advancement, regulatory acceptability, and interdisciplinary cooperation.

Introduction

Tissue engineering and three-dimensional (3D) micro physiological disease models are revolutionary developments in pharmaceutical and biomedical research. These technologies' main goal is to replicate human tissue and organ functioning in vitro with a degree of physiological relevance that was not possible with traditional experimental

models. The process of finding and developing new drugs is time-consuming, costly, and risky. Many candidate compounds fail clinical trials because they are ineffective or unexpectedly harmful.

The inadequate predictive ability of conventional preclinical models is one of the primary causes of these failures. To create illness models that are applicable to humans, 3D micro physiological systems (MPS) combine concepts from cell biology, biomaterials science, microengineering, and tissue engineering. Important features of natural tissue microenvironments, including as three-dimensional architecture, mechanical pressures, metabolic gradients, and dynamic cell–cell and cell–matrix interactions, are replicated in these systems. They thereby offer a more realistic depiction of human physiology and pathology.

These sophisticated models have drawn a lot of interest lately for a variety of uses, from high-throughput drug screening and tailored treatment to basic disease mechanism research. The idea of precision medicine, in which treatments are customized for each patient according to their distinct biological traits, is further supported by 3D micro physiological models that integrate patient-derived cells with stem cell technology.

Limitations of Conventional Disease Models

For many years, conventional disease models have served as the cornerstone of biomedical research; nevertheless, they have intrinsic flaws that drastically lower their ability to predict human outcomes. The intricate three-dimensional structure of tissues cannot be replicated by two-dimensional (2D) cell culture techniques, which cultivate cells on flat plastic surfaces. Cells in these conditions differ from their in vivo counterparts in terms of shape, polarity, gene expression, and metabolic activity. Drug responses shown in 2D cells hence frequently do not correspond with clinical results.

Despite being more complicated than in vitro systems, animal models have significant disadvantages as well. Animal data and human clinical outcomes often differ due to differences in species-specific physiology, genetics, immunological responses, and medication metabolism. High attrition rates and higher development costs result from the failure of many medications that show safety and effectiveness in animal research in human trials. The widespread use of animal models is further constrained by ethical issues, lengthy experimental schedules, and regulatory demands.

These drawbacks highlight how urgently different, human-relevant experimental platforms are needed. Many of these issues are addressed by 3D micro physiological disease models, which use human cells in biomimetic settings to more accurately simulate tissue-level processes and disease states.



Fig: Comparison of Conventional Disease Models and 3D Micro physiological Systems

Concept of Micro physiological Systems (MPS)

Micro physiological systems are sophisticated in vitro platforms created to replicate, at the microscale, the structural and functional complexity of human organs. These systems combine constructed microenvironments that offer suitable chemical, biological, and physical stimuli with living human cells. Instead of only preserving cell viability, the fundamental idea of MPS is to mimic important physiological processes.

Microfluidic tubes that mimic blood flow are frequently incorporated into MPS platforms, allowing for continuous waste removal and nutrient delivery. Long-term cell viability and function are supported by this dynamic milieu, which is crucial for research on chronic toxicity and the analysis of disease progression. Furthermore, MPS enables exact control over variables that are crucial in determining tissue behaviour, such as oxygen content, mechanical strain, and shear stress.

Micro physiological systems bridge the gap between conventional cell culture and whole-animal research by simulating organ-level responses in a regulated in vitro environment. For medication development and translational research, they offer a scalable, repeatable, and morally acceptable substitute.

Fundamentals of 3D Cell Culture Technology

With the use of three-dimensional cell culture technology, cells are grown in a spatial environment that permits interactions in all directions and closely mimics the architecture of natural tissue. In contrast to 2D cultures, 3D systems allow cells to create intricate multicellular structures including tissue-like constructions, organoids, and spheroids. Similar to those found in vivo, these structures display gradients of oxygen, nutrients, and signaling chemicals.

Scaffold-based systems, scaffold-free spheroid cultures, and hydrogel-based matrices are some of the techniques used in 3D cell culture. While scaffold-free systems rely on cell self-assembly, scaffold-based systems guide tissue organization and offer mechanical support. Because they can replicate the viscoelastic characteristics of the extracellular matrix, hydrogels made of synthetic or natural polymers are especially useful.

A key element of contemporary disease modelling and tissue engineering techniques, 3D cell culture technology improves cellular differentiation, functioning, and medication responsiveness.



Fig: Fundamentals of Three-Dimensional Cell Culture Technology

Role of Extracellular Matrix in Tissue Engineering

The intricate web of proteins, glycoproteins, and polysaccharides known as the extracellular matrix (ECM) gives cells structural and metabolic support. The extracellular matrix (ECM) controls vital cellular functions in native tissues, including adhesion, migration, proliferation, differentiation, and death. Therefore, successful tissue engineering and disease modelling depend on exact replication of ECM characteristics.

ECM elements are carefully chosen or designed to replicate tissue-specific properties in 3D micro physiological models. While synthetic materials offer exact control over stiffness, disintegration rate, and chemical composition, natural ECM-derived materials like collagen, laminin, and fibrin support cell adhesion and biocompatibility. The ECM's mechanical characteristics, such as its stiffness and elasticity, are critical to the development of diseases, especially fibrosis and cancer.

Tissue-engineered models attain better physiological relevance by replicating the biochemical and mechanical cues of the native extracellular matrix (ECM), allowing for more precise study of disease causes and treatment responses.



Fig: Role of Extracellular Matrix and Biomaterials in Tissue Engineering

Biomaterials Used in 3D Micro physiological Models

Because they supply the physical structure and biochemical cues needed for tissue creation and function, biomaterials are essential to 3D micro physiological systems. Cell viability, differentiation, mechanical stability, and the long-term functionality of created tissues are all directly impacted by the choice of biomaterials. Natural, synthetic, and hybrid biomaterials are the three main categories of biomaterials utilized in MPS; each has unique benefits and drawbacks.

Collagen, gelatine, alginate, chitosan, fibrin, and Matrigel are examples of natural biomaterials that promote cell adhesion, migration, and physiological signalling because they closely match native extracellular matrix components. Although these materials support diverse cell activities and are highly biocompatible, they frequently have limited mechanical tunability and batch-to-batch variability. Polyethylene glycol (PEG), polylactic acid (PLA), polyglycolic acid (PGA), and polycaprolactone (PCL) are examples of synthetic biomaterials that offer better control over

mechanical characteristics, degradation rates, and structural repeatability. However, in order to facilitate ideal cell interactions, they might need to be functionalized with bioactive chemicals.

Hybrid biomaterials offer both mechanical accuracy and biological functionality by combining natural and synthetic components. These biomaterials make it possible to recreate tissue-specific microenvironments in 3D micro physiological models, which enhances model robustness and predictive accuracy in drug screening applications.

Tissue Engineering Principles Applied to Disease Modelling

Three essential elements—cells, scaffolds, and bioactive signals—are strategically integrated to form the foundation of tissue engineering. These concepts enable the reconstruction of diseased tissue states in a regulated in vitro setting when used in disease modelling. To replicate disease-specific cellular phenotypes, human primary cells, stem cells, or genetically modified cells are integrated into artificial scaffolds.

Growth factors, cytokines, and mechanical stimuli are examples of bioactive signals that are carefully controlled to elicit behaviours related to disease. For instance, to mimic pathological ECM remodelling, fibrotic illness models include profibrotic signalling molecules and enhanced matrix stiffness. In a similar vein, tumour models incorporate immunological elements, aberrant vascular architecture, and stromal cells to represent the complexity of the tumour microenvironment.

Disease models can represent dynamic disease development instead of static endpoints by utilizing tissue engineering concepts. This capacity increases translational relevance and is especially useful for researching long-term medication effects, treatment resistance, and chronic disorders.

Organ-on-Chip Technology Overview

Organ-on-chip technology is an advanced subclass of micro physiological systems that mimic the shape and function of organs using microfabricated devices. Usually made of clear polymers, these chips have microchannels lined with human cells. Continuous perfusion is made possible by the microfluidic architecture, which simulates physiological shear stress and blood flow.

The ability of organ-on-chip systems to integrate mechanical forces including stretching, compression, and fluid-induced stress is one of their distinguishing characteristics. For instance, heart-on-chip systems replicate cyclic contractions, whereas lung-on-chip models mimic breathing motions. Real-time physiological parameter monitoring, such as barrier integrity, electrical activity, and metabolic output, is made possible by integrated sensors.

Organ-on-chip platforms are effective tools for disease modelling, toxicity evaluation, and mechanism-based drug discovery because they offer unmatched control and observation of human tissue behaviour.



Fig: Schematic Representation of Organ-on-Chip Technology

3D Disease Modelling in Cancer Research

Conventional 2D culture techniques do a poor job of capturing the complexity and heterogeneity of cancer. Tumour architecture, cellular heterogeneity, hypoxic gradients, and interactions with the Tumour microenvironment are more precisely replicated in three-dimensional cancer models. Tumour-on-chip platforms, organoids, and Tumour spheroids are examples of these models.

Cancer cells interact with stromal fibroblasts, endothelial cells, and immune cells in three-dimensional Tumour models, simulating important elements of Tumour growth and spread. Realistic drug penetration barriers and resistance mechanisms are influenced by hypoxia-induced signalling pathways and extracellular matrix remodelling. Drug responses seen in 3D models therefore frequently have a stronger correlation with clinical results.

The efficiency and dependability of oncology drug development are increased by the widespread use of 3D cancer disease models for anticancer agent screening, metastatic behaviour research, and combination therapy evaluation.

Cardiovascular Disease Modelling Using MPS

Accurate and predictive experimental models are necessary since cardiovascular illnesses continue to be a major cause of death worldwide. Essential aspects of heart and vascular function, such as myocardial contractility, electrical conduction, and hemodynamic forces, are replicated in micro physiological cardiovascular models. To assure human relevance, these systems frequently include cardiomyocytes generated from human induced pluripotent stem cells.

Real-time measurements of contractile force, electrical activity, and pharmacological drug responses are made possible by heart-on-a-chip devices. Vascular models mimic blood flow, endothelial function, and inflammatory reactions linked to hypertension and atherosclerosis. Crucially, one of the main causes of late-stage drug failure is drug-induced cardiotoxicity, to which these systems are extremely vulnerable.

Cardiovascular micro physiological systems greatly improve drug development and enable customized cardiovascular therapy design by offering mechanistic insights and early safety evaluation.

Integration of Microfluidics in 3D Micro physiological Systems

One characteristic that distinguishes micro physiological systems is microfluidics, which allows for exact control over the cellular microenvironment. Continuous nutrition delivery, oxygen supply, and waste elimination are made possible via microfluidic channels, which mimic blood flow. Long-term tissue viability and functionality are supported by this dynamic flow environment.

The creation of chemical gradients, shear stress, and mechanical stimulation—all of which affect cell activity and the course of disease—is made possible by the integration of microfluidics. Additionally, real-time sampling and analysis of secreted biomarkers are made possible by microfluidic technologies, allowing for ongoing tissue response monitoring.

Microfluidics greatly improves the realism and prediction ability of 3D micro physiological illness models by simulating physiological circulation and inter-organ communication.

Drug Screening Using 3D Micro physiological Models

One of the most significant uses of 3D micro physiological systems is drug screening. These models offer a platform that is relevant to humans for assessing the pharmacokinetic behaviour, toxicity, and efficacy of drugs. Because 3D systems have realistic tissue architecture and microenvironmental circumstances, they predict clinical drug responses more precisely than 2D cultures.

Long-term toxicity, off-target effects, and dose-response relationships can all be evaluated by micro physiological drug screening. The comprehensive investigation of drug absorption, distribution, metabolism, and excretion is further made possible by multi-organ MPS systems. This all-encompassing strategy increases translational success and lessens reliance on animal testing.

3D micro physiological drug screening technologies are revolutionizing pharmaceutical research by improving prediction accuracy and lowering development costs.

Personalized Therapy and Patient-Specific Models

The goal of personalized therapy is to customize medical care based on each patient's unique biological traits. By making it possible to create patient-specific disease models utilizing primary human cells or induced pluripotent stem cells (iPSCs), three-dimensional micro physiological systems are essential to the advancement of personalized medicine. These models enable precise prediction of individual medication reactions by maintaining the donor's genetic background, molecular markers, and behavioural characteristics.

Ex vivo testing of various therapy options prior to clinical administration is made possible by patient-derived organoids and organ-on-chip platforms. This method is particularly useful in oncology, uncommon genetic disorders, and chronic illnesses where treatment response varies greatly between patients. Additionally, customized micro physiological models help with toxicity prediction and dose optimization, which lowers the possibility of negative medication reactions.

3D micro physiological systems greatly increase precision medicine and lead to better clinical outcomes by integrating patient-specific biology into drug screening and disease modelling.



Fig: Personalized Therapy and Artificial Intelligence Integration

Role of Omics and Data Integration

Genomics, transcriptomics, proteomics, and metabolomics are examples of omics technologies that offer thorough biological insights into disease causes and treatment outcomes. Omics techniques allow for multidimensional investigation of cellular and tissue-level responses under healthy and pathological situations when combined with 3D micro physiological systems. The identification of illness biomarkers, biological pathways, and prediction signatures linked to therapeutic efficacy or toxicity is made easier by combining omics data with micro physiological models. Large datasets produced by these systems are analysed using sophisticated bioinformatics and computational methods, allowing for a systems-level comprehension of intricate biological processes. Combining omics technologies with 3D disease models facilitates rational drug design, improves model validation, and speeds up the creation of individualized treatment plans.

Artificial Intelligence in 3D Disease Modelling

The technologies of machine learning (ML) and artificial intelligence (AI) have developed into effective instruments for the analysis of intricate datasets produced by 3D micro physiological systems. Large amounts of imaging, functional, and molecular data may be processed by AI-driven algorithms to find patterns and accurately forecast medication reactions.

AI is frequently used in 3D disease modelling for image analysis, phenotypic classification, and illness progression prediction. To produce predictive insights into treatment outcomes, machine learning models combine information from omics, clinical databases, and micro physiological systems. By connecting biological and physical elements, AI also helps optimize system design.

Drug discovery is accelerated, experimental costs are decreased, and translational success is increased when AI is integrated with 3D micro physiological platforms.

Regulatory Perspective and Industry Adoption

The utility of micro physiological systems as sophisticated preclinical models is becoming more widely acknowledged by regulatory bodies and the pharmaceutical industry. Programs to analyse and validate these systems for drug safety and efficacy evaluation have been started by agencies including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). 3D micro physiological models are being used by pharmaceutical corporations to shorten the time, expense, and failure rate of drug development. Standardization, validation, and benchmarking of these platforms are the main goals of cooperative initiatives between academics, business, and regulatory agencies. Strong proof of reproducibility, dependability, and physiological significance is necessary for regulatory adoption. Micro physiological systems are anticipated to become essential parts of drug development pipelines as regulatory frameworks change.

Ethical Considerations and Reduction of Animal Testing

In biomedical research, ethical issues are becoming more and more crucial, especially when it comes to using animals in experiments. The 3Rs—Replacement, Reduction, and Refinement—are strongly supported by three-dimensional micro physiological systems, which offer useful substitutes for animal models. These technologies erase species-specific disparities and lessen animal suffering by utilizing human-derived cells and tissues. The number of

experimental subjects needed is greatly decreased by using micro physiological models, which enable repeated testing on the same platform. The ethical benefits of 3D micro physiological illness modelling support its status as a sustainable and responsible method of contemporary drug discovery.

Challenges in 3D Micro physiological Modelling

Despite significant progress, a number of obstacles prevent 3D micro physiological systems from being widely used. The need for specialized knowledge, expensive expenses, and technical complexity continue to be major obstacles. Reproducibility between labs may be impacted by variations in cell sources, biomaterials, and manufacturing processes. Additional difficulties include the scalability and long-term stability of complicated tissue models. Research on the integration of immunological, endocrine, and neurological system components is still ongoing. For wider adoption, addressing these issues through standardization, technological innovation, and interdisciplinary cooperation is crucial.

Future Perspectives and Technological Advancements

Rapid technical advancement is driving the future of 3D micro physiological disease modelling. Multi-organ and body-on-a-chip platforms that mimic systemic physiological responses are examples of emerging advancements. Tissue functionality will be further enhanced by developments in biomaterials, such as intelligent and stimuli-responsive materials. Continuous monitoring and predictive modelling will be made possible by the integration of digital twins, sophisticated imaging methods, and real-time biosensors. Personalized therapy design will be further improved by combining these technologies with artificial intelligence. It is anticipated that these developments will increase the translational influence of micro physiological systems.

Fig: Future Trends in 3D Micro physiological Disease Modelling and Precision Medicine

Clinical Translation and Impact on Healthcare

Healthcare could be revolutionized by the clinical application of 3D micro physiological systems. Enhancing patient safety, cutting down on time, and lowering drug development costs are all possible with improved predictive accuracy in preclinical testing. Personalized illness models help doctors make evidence-based clinical decisions by allowing them to assess therapy responses prior to treatment. These systems are especially useful for chronic illnesses, uncommon diseases, and cancer. Micro physiological systems are anticipated to have a major impact on customized healthcare and precision medicine as clinical validation grows.

Conclusion

Tissue engineering and three-dimensional micro physiological disease modelling are revolutionary developments in individualized treatment and medication discovery.

These systems eliminate many of the drawbacks of traditional preclinical models by precisely simulating human tissue architecture, cellular interactions, and physiological dynamics.

These platforms' prediction capabilities have been greatly improved by the incorporation of biomaterials, microfluidics, omics technologies, and artificial intelligence.

Despite current obstacles, widespread acceptance is anticipated to be fuelled by ongoing innovation and regulatory assistance.

All things considered, 3D micro physiological systems provide a more moral, effective, and patient-centred method of medication creation and medical care.

References

Tissue Engineering Vunjak-Novakovic G, Ronaldson-Bouchard K, Radisic M. Organs-on-a-chip models for biological research. Cell. 2021.

Tissue Engineering Bein A, Shin W, Jalili-Firoozinezhad S, et al. Microfluidic Organ-on-a-Chip Models of Human Intestine. Cellular and Molecular Gastroenterology and Hepatology. 2018.

Tissue Engineering Sun W, Luo Z, Lee J, et al. Organ-on-a-Chip for Cancer and Immune System Modeling. Advanced Healthcare Materials. 2022.

Tissue Engineering Hofer M, Lutolf MP. Engineering organoids. Nature Reviews Materials. 2021.

Tissue Engineering Nikolaev M, Mitrofanova O, Broguiere N, et al. Homeostatic mini-intestines through scaffold-guided organoid morphogenesis. Nature. 2020.

Tissue Engineering Holloway EM, Capeling MM, Spence JR. Biologically inspired approaches to enhance human organoid complexity. Development. 2019.

Tissue Engineering Lee J, Choi B, No DY, et al. A high-throughput microfluidic platform for 3D tumor models. Nature Biomedical Engineering. 2021.

Tissue Engineering Kapałczyńska M, Kolenda T, Przybyła W, et al. 2D and 3D cell cultures – a comparison of different types of cancer cell cultures. Archives of Medical Science. 2018.

Tissue Engineering Richards DJ, Li Y, Kerr CM, et al. Human cardiac organoids for disease modeling. Nature Biomedical Engineering. 2020.

Tissue Engineering Paek J, Park SE, Lu Q, et al. Microphysiological engineering of self-assembled and perfusable microvascular beds. Science Advances. 2019.

Tissue Engineering Skardal A, Murphy SV, Devarasetty M, et al. Multi-tissue interactions in an integrated human organ-on-chip platform. Scientific Reports. 2017.

Tissue Engineering Yin X, Mead BE, Safaee H, et al. Engineering Stem Cell Organoids. Cell Stem Cell. 2016.

Tissue Engineering Noor N, Shapira A, Edri R, et al. 3D Printing of Personalized Thick and Perfusable Cardiac Patches. Advanced Science. 2019.

Tissue Engineering Daly AC, Prendergast ME, Hughes AJ, Burdick JA. Bioprinting for the Biologist. Cell. 2021.

Tissue Engineering Matai I, Kaur G, Seyedsalehi A, et al. Progress in 3D Bioprinting Technology for Tissue/Organ Regeneration. Materials Science and Engineering C. 2020.